What type of study is this?

This is a Phase 2 study (also classified as: Human Clinical Trial, Pre-Registered Trial).

August 18, 2025Antimicrobial Agents and ChemotherapyOpen Access

Cytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b study

View Full Paper

Ask AI

Bookmark

Authors

AGAndreas H. GrollUniwersytecki Szpital Dziecięcy LDLara Danziger‐IsakovCincinnati Children's Hospital Medical Center AGAharon GefenRambam Health Care Campus

Discussion

Member takes

Implication

Phase 2b study finds letermovir effective for preventing CMV in pediatric hematopoietic cell transplant patients, indicating safety and pharmacokinetics align with adult data.

Key Points

Letermovir was found effective and safe for preventing CMV in pediatric hematopoietic cell transplant recipients.
In a Phase 2b trial with 65 participants, dosage adjustments ensured pharmacokinetics were within adult reference ranges.
The pediatric population pharmacokinetic model helped optimize dosing recommendations for letermovir.
Efficacy and safety outcomes in pediatric patients were largely consistent with those seen in adults undergoing hematopoietic cell transplants.

Cite This Study

Groll et al. (2025) studied this question.

synapsesocial.com/papers/68af431bad7bf08b1ead18d7 https://doi.org/10.1128/aac.00420-25

View Full Paper

Ask AI

Bookmark

Implication

Phase 2b study finds letermovir effective for preventing CMV in pediatric hematopoietic cell transplant patients, indicating safety and pharmacokinetics align with adult data.

Cytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b study

Discussion

Member takes

Implication

Key Points

Cite This Study

Cytomegalovirus prophylaxis with letermovir in pediatric (birth to <18 years of age) hematopoietic cell transplant recipients: pharmacokinetics, efficacy, and safety results of a Phase 2b study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider